LYELL IMMUNOPHARMA INC (LYEL) Fundamental Analysis & Valuation

NASDAQ:LYEL • US55083R2031

Current stock price

21.55 USD
+1.49 (+7.43%)
Last:

This LYEL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. LYEL Profitability Analysis

1.1 Basic Checks

  • LYEL had negative earnings in the past year.
  • In the past year LYEL has reported a negative cash flow from operations.
  • LYEL had negative earnings in each of the past 5 years.
  • LYEL had a negative operating cash flow in each of the past 5 years.
LYEL Yearly Net Income VS EBIT VS OCF VS FCFLYEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M -300M

1.2 Ratios

  • LYEL's Return On Assets of -80.71% is on the low side compared to the rest of the industry. LYEL is outperformed by 67.50% of its industry peers.
  • With a Return On Equity value of -110.57%, LYEL perfoms like the industry average, outperforming 41.78% of the companies in the same industry.
Industry RankSector Rank
ROA -80.71%
ROE -110.57%
ROIC N/A
ROA(3y)-60.62%
ROA(5y)-44.72%
ROE(3y)-78.66%
ROE(5y)-56.98%
ROIC(3y)N/A
ROIC(5y)N/A
LYEL Yearly ROA, ROE, ROICLYEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for LYEL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LYEL Yearly Profit, Operating, Gross MarginsLYEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 -200K -400K -600K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. LYEL Health Analysis

2.1 Basic Checks

  • LYEL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • LYEL has more shares outstanding than it did 1 year ago.
  • LYEL has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for LYEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LYEL Yearly Shares OutstandingLYEL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
LYEL Yearly Total Debt VS Total AssetsLYEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • LYEL has an Altman-Z score of -4.81. This is a bad value and indicates that LYEL is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -4.81, LYEL is doing worse than 62.09% of the companies in the same industry.
  • LYEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.81
ROIC/WACCN/A
WACC9.29%
LYEL Yearly LT Debt VS Equity VS FCFLYEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M 800M

2.3 Liquidity

  • LYEL has a Current Ratio of 5.28. This indicates that LYEL is financially healthy and has no problem in meeting its short term obligations.
  • LYEL has a Current ratio (5.28) which is comparable to the rest of the industry.
  • A Quick Ratio of 5.28 indicates that LYEL has no problem at all paying its short term obligations.
  • LYEL's Quick ratio of 5.28 is in line compared to the rest of the industry. LYEL outperforms 58.41% of its industry peers.
Industry RankSector Rank
Current Ratio 5.28
Quick Ratio 5.28
LYEL Yearly Current Assets VS Current LiabilitesLYEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. LYEL Growth Analysis

3.1 Past

  • The earnings per share for LYEL have decreased by -1.65% in the last year.
  • LYEL shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -40.98%.
  • LYEL shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -65.86% yearly.
EPS 1Y (TTM)-1.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-87.5%
Revenue 1Y (TTM)-40.98%
Revenue growth 3Y-92.48%
Revenue growth 5Y-65.86%
Sales Q2Q%-45.45%

3.2 Future

  • The Earnings Per Share is expected to grow by 21.18% on average over the next years. This is a very strong growth
  • LYEL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 626.78% yearly.
EPS Next Y42.51%
EPS Next 2Y21.18%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-60.22%
Revenue Next 2Y735.25%
Revenue Next 3Y1032.99%
Revenue Next 5Y626.78%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LYEL Yearly Revenue VS EstimatesLYEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 20M 40M 60M 80M 100M
LYEL Yearly EPS VS EstimatesLYEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -5 -10 -15 -20 -25

More info and screens

Find the best growth stocksShow best growing peers

1

4. LYEL Valuation Analysis

4.1 Price/Earnings Ratio

  • LYEL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year LYEL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LYEL Price Earnings VS Forward Price EarningsLYEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LYEL Per share dataLYEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10 -15

4.3 Compensation for Growth

  • LYEL's earnings are expected to grow with 21.18% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.18%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LYEL Dividend Analysis

5.1 Amount

  • No dividends for LYEL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LYEL Fundamentals: All Metrics, Ratios and Statistics

LYELL IMMUNOPHARMA INC

NASDAQ:LYEL (4/1/2026, 2:32:01 PM)

21.55

+1.49 (+7.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12
Earnings (Next)05-11
Inst Owners55.99%
Inst Owner Change18.94%
Ins Owners0.72%
Ins Owner Change0.31%
Market Cap502.33M
Revenue(TTM)36.00K
Net Income(TTM)-274.45M
Analysts77.78
Price Target40.12 (86.17%)
Short Float %5.95%
Short Ratio9.18
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-104.27%
Min EPS beat(2)-229.52%
Max EPS beat(2)20.98%
EPS beat(4)3
Avg EPS beat(4)-46.01%
Min EPS beat(4)-229.52%
Max EPS beat(4)20.98%
EPS beat(8)5
Avg EPS beat(8)-22.6%
EPS beat(12)9
Avg EPS beat(12)-6.47%
EPS beat(16)13
Avg EPS beat(16)4.86%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.16%
PT rev (3m)32.58%
EPS NQ rev (1m)-3.79%
EPS NQ rev (3m)-3.79%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13953.63
P/FCF N/A
P/OCF N/A
P/B 2.02
P/tB 2.02
EV/EBITDA N/A
EPS(TTM)-16.06
EYN/A
EPS(NY)-9.23
Fwd EYN/A
FCF(TTM)-8.24
FCFYN/A
OCF(TTM)-6.44
OCFYN/A
SpS0
BVpS10.65
TBVpS10.65
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -80.71%
ROE -110.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-60.62%
ROA(5y)-44.72%
ROE(3y)-78.66%
ROE(5y)-56.98%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 363.77%
Cap/Sales 116597%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.28
Quick Ratio 5.28
Altman-Z -4.81
F-Score2
WACC9.29%
ROIC/WACCN/A
Cap/Depr(3y)179.69%
Cap/Depr(5y)230.94%
Cap/Sales(3y)56937%
Cap/Sales(5y)34290.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-87.5%
EPS Next Y42.51%
EPS Next 2Y21.18%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-40.98%
Revenue growth 3Y-92.48%
Revenue growth 5Y-65.86%
Sales Q2Q%-45.45%
Revenue Next Year-60.22%
Revenue Next 2Y735.25%
Revenue Next 3Y1032.99%
Revenue Next 5Y626.78%
EBIT growth 1Y9.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-4.4%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y1.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.62%
OCF growth 3YN/A
OCF growth 5YN/A

LYELL IMMUNOPHARMA INC / LYEL Fundamental Analysis FAQ

What is the ChartMill fundamental rating of LYELL IMMUNOPHARMA INC (LYEL) stock?

ChartMill assigns a fundamental rating of 3 / 10 to LYEL.


What is the valuation status for LYEL stock?

ChartMill assigns a valuation rating of 1 / 10 to LYELL IMMUNOPHARMA INC (LYEL). This can be considered as Overvalued.


Can you provide the profitability details for LYELL IMMUNOPHARMA INC?

LYELL IMMUNOPHARMA INC (LYEL) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for LYEL stock?

The Earnings per Share (EPS) of LYELL IMMUNOPHARMA INC (LYEL) is expected to grow by 42.51% in the next year.